Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellular Senescence | 8 | 2026 | 121 | 4.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2026 | 128 | 3.040 |
Why?
|
| Pancreatic Neoplasms | 6 | 2026 | 354 | 2.470 |
Why?
|
| Tumor Microenvironment | 12 | 2026 | 183 | 2.330 |
Why?
|
| Prostatic Neoplasms | 7 | 2026 | 501 | 1.990 |
Why?
|
| Killer Cells, Natural | 4 | 2026 | 220 | 1.720 |
Why?
|
| Neoplasms | 7 | 2025 | 1376 | 1.490 |
Why?
|
| Immunologic Surveillance | 2 | 2025 | 22 | 1.480 |
Why?
|
| Immunotherapy | 8 | 2026 | 274 | 1.420 |
Why?
|
| Cell Line, Tumor | 15 | 2026 | 1573 | 1.410 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2025 | 46 | 1.360 |
Why?
|
| Mice | 23 | 2026 | 11171 | 1.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 84 | 1.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2026 | 58 | 0.930 |
Why?
|
| Thiolester Hydrolases | 1 | 2025 | 10 | 0.920 |
Why?
|
| Stromal Cells | 1 | 2026 | 78 | 0.910 |
Why?
|
| Antigens, Neoplasm | 1 | 2026 | 134 | 0.910 |
Why?
|
| Animals | 26 | 2026 | 21449 | 0.910 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2025 | 169 | 0.870 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 113 | 0.870 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 710 | 0.830 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 314 | 0.820 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2025 | 234 | 0.820 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 170 | 0.810 |
Why?
|
| Cell Lineage | 1 | 2025 | 282 | 0.790 |
Why?
|
| Endothelial Cells | 1 | 2025 | 215 | 0.760 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2024 | 138 | 0.760 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 350 | 0.750 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 74 | 0.750 |
Why?
|
| Membrane Proteins | 2 | 2025 | 925 | 0.740 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 12 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 18 | 0.730 |
Why?
|
| Cytokines | 1 | 2026 | 964 | 0.710 |
Why?
|
| Macrophages | 2 | 2025 | 1041 | 0.710 |
Why?
|
| Nanoparticles | 2 | 2026 | 551 | 0.700 |
Why?
|
| Immunity, Innate | 2 | 2024 | 829 | 0.690 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 23 | 0.620 |
Why?
|
| RNA, Messenger | 1 | 2026 | 1580 | 0.620 |
Why?
|
| Cytostatic Agents | 1 | 2018 | 1 | 0.580 |
Why?
|
| Signal Transduction | 7 | 2025 | 3162 | 0.540 |
Why?
|
| Humans | 25 | 2026 | 65630 | 0.500 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2025 | 65 | 0.480 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 29 | 0.460 |
Why?
|
| Indoles | 1 | 2015 | 112 | 0.450 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2018 | 89 | 0.440 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2026 | 679 | 0.440 |
Why?
|
| Mesoderm | 1 | 2015 | 89 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 466 | 0.430 |
Why?
|
| Aging | 1 | 2020 | 775 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 588 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 4 | 2026 | 3500 | 0.380 |
Why?
|
| Neoplasm Metastasis | 5 | 2025 | 223 | 0.330 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1010 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2018 | 213 | 0.320 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 45 | 0.300 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 2319 | 0.300 |
Why?
|
| Phenotype | 2 | 2024 | 1235 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 196 | 0.280 |
Why?
|
| Male | 9 | 2026 | 31281 | 0.240 |
Why?
|
| Mice, Transgenic | 4 | 2024 | 1291 | 0.240 |
Why?
|
| Neuroblastoma | 1 | 2026 | 54 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2025 | 22 | 0.230 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2025 | 37 | 0.230 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2025 | 61 | 0.230 |
Why?
|
| Cholangiocarcinoma | 1 | 2025 | 36 | 0.230 |
Why?
|
| Bile Duct Neoplasms | 1 | 2025 | 60 | 0.220 |
Why?
|
| Immunoconjugates | 1 | 2025 | 95 | 0.220 |
Why?
|
| Cell Plasticity | 1 | 2025 | 24 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2025 | 53 | 0.220 |
Why?
|
| Tumor Escape | 1 | 2024 | 16 | 0.220 |
Why?
|
| Cell Proliferation | 4 | 2025 | 1042 | 0.200 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 17 | 0.200 |
Why?
|
| Disease Progression | 2 | 2026 | 1225 | 0.200 |
Why?
|
| Dendritic Cells | 1 | 2026 | 531 | 0.190 |
Why?
|
| Genetic Engineering | 1 | 2024 | 114 | 0.190 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 184 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2024 | 135 | 0.190 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 228 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2025 | 414 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2024 | 198 | 0.180 |
Why?
|
| Calcium | 1 | 2025 | 584 | 0.170 |
Why?
|
| Mitochondria | 1 | 2025 | 413 | 0.170 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2168 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 644 | 0.160 |
Why?
|
| Genes, ras | 1 | 2020 | 28 | 0.160 |
Why?
|
| Gene Editing | 1 | 2024 | 331 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 87 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2018 | 18 | 0.140 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 54 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 43 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 34 | 0.140 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 2 | 0.140 |
Why?
|
| Pyridones | 1 | 2018 | 42 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2020 | 148 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2018 | 55 | 0.140 |
Why?
|
| Piperazines | 1 | 2018 | 86 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 235 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 203 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 129 | 0.140 |
Why?
|
| Lung | 1 | 2023 | 969 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 120 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 198 | 0.130 |
Why?
|
| Female | 3 | 2026 | 34293 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 604 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 38 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 178 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2015 | 518 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 542 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2015 | 611 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 216 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 526 | 0.110 |
Why?
|
| Stem Cells | 1 | 2016 | 276 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1100 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2014 | 186 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 797 | 0.090 |
Why?
|
| ras Proteins | 1 | 2012 | 76 | 0.090 |
Why?
|
| Mutation | 1 | 2018 | 2670 | 0.080 |
Why?
|
| Histocompatibility Antigens | 1 | 2025 | 107 | 0.060 |
Why?
|
| Snail Family Transcription Factors | 1 | 2025 | 29 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2025 | 167 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2025 | 103 | 0.050 |
Why?
|
| HMGB1 Protein | 1 | 2024 | 26 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2025 | 181 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 74 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2024 | 435 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2022 | 22 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 333 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 39 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 194 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 897 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 565 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 154 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 195 | 0.030 |
Why?
|
| Arginase | 1 | 2014 | 7 | 0.030 |
Why?
|
| Anisoles | 1 | 2014 | 3 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 19 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 33 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2014 | 30 | 0.030 |
Why?
|
| Epithelium | 1 | 2014 | 100 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 61 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2014 | 98 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 144 | 0.020 |
Why?
|
| Prostate | 1 | 2014 | 124 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 376 | 0.020 |
Why?
|
| Spleen | 1 | 2014 | 476 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 274 | 0.020 |
Why?
|
| CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 35 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 40 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 58 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 754 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2189 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 132 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 391 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1195 | 0.020 |
Why?
|